Jefferies Backs 6 Healthcare Stocks Despite Hospital Selloff

Hospital stocks have faced headwinds recently, extending losses amid regulatory scrutiny over cancer-drug markups and pharmacy practices, according to reports. Despite the broader sector selloff, Jefferies maintained constructive positions on the healthcare space. The brokerage has kept Buy ratings on six healthcare companies, indicating confidence in their valuations and growth prospects. Target-price upside for these holdings ranges from 22% to 46%, suggesting meaningful appreciation potential from current levels. Beyond near-term price targets, Jefferies cited strong projected EBITDA growth through FY29 as a key driver of its bullish thesis, indicating the brokerage expects these companies to demonstrate improving operational performance over the medium term.

The healthcare sector often attracts regulatory attention due to pricing practices and pharmaceutical economics, which can create volatility and create opportunities for investors. When sector headwinds intensify, such as those related to drug pricing scrutiny, quality research firms often differentiate between companies with sustainable competitive advantages and those more vulnerable to regulatory pressure. Investors monitoring hospital stocks and healthcare equities generally watch for regulatory developments, pricing trends, and EBITDA growth trajectories as key metrics for capital allocation decisions. The presence of upside targets ranging toward 46% suggests Jefferies identifies meaningful risk-reward imbalances in certain names, potentially indicating valuations have overshot fundamental potential in parts of the selloff.

Source: Markets-Economic Times